A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults

← catalyst calendar

NCT07622433 · readout in 19 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase

Phase 1

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

18actual

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-06-10

actual

When the study began enrolling

Primary completion

2026-09-07

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-09-07

estimated

The whole study's end, after follow-up

First posted

2026-06-03

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-28

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Healthy Participants

Interventions

Drug: Laroprovstat/ezetimibe FCDP
Drug: Laroprovstat STP
Drug: Ezetimibe STP
Drug: Laroprovstat/ezetimibe FCDP-slow variant

Primary outcomes

what the primary-completion date above is the date OF

Area under concentration-time curve from time 0 to infinity (AUCinf)

measured Day 1 to 11 of Treatment Periods 1, 2, 3, and 4 (each treatment period is 11 days)

Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)

measured Day 1 to 11 of Treatment Periods 1, 2, 3, and 4 (each treatment period is 11 days)

Maximum observed drug concentration (Cmax)

measured Day 1 to 11 of Treatment Periods 1, 2, 3, and 4 (each treatment period is 11 days)

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed